The map of drug-development layoffs: Research Triangle, Boston, and the coasts

Every WARN filing carries a location, which means the public layoff record is also a map. Plot the drug-development filings from the last few years and they do not scatter evenly. They cluster in a handful of places, and the clusters tell you where the industry's physical footprint, and its pain, is concentrated.

The Research Triangle is the capital

Durham and the surrounding North Carolina research corridor is the center of gravity for clinical research, and the filings show it. IQVIA's one notable WARN notice, 232 people in 2021, was in Durham. Parexel's largest historical filing, 125 people in 2015, was in Durham. Fortrea is headquartered there. PRA Health Sciences, now part of ICON, was built there. Charles River has filed in Durham too. When people say clinical research runs through the Research Triangle, the layoff record is one more piece of evidence: this is where the jobs are, so this is where the cuts register.

If you work in the Triangle, this cuts both ways. The density means opportunity, because when one employer trims, three others recruit from the same pool. It also means concentration risk, because a regional slowdown hits your whole professional network at once.

The Boston corridor is the preclinical cluster

Massachusetts shows up repeatedly, but read it carefully. Charles River's Wilmington headquarters has filed round after round through 2025 and 2026, and Thermo Fisher has cut in Cambridge, Plainville, and Lexington. These are largely preclinical, safety-assessment, and bioproduction sites, not clinical trial services. The Boston cluster is real, but it is the upstream, laboratory side of drug development, and it is a leading indicator for the clinical side rather than the same thing.

The coasts carry the manufacturing cuts

California and Florida account for much of the recent volume, almost all of it manufacturing and instruments rather than clinical. Thermo Fisher's Carlsbad, California site alone accounts for well over 200 people across recent filings, with more in Orlando and Alachua, Florida. These are the bioproduction and life-sciences-tools cuts that track the broader slowdown in R&D spending.

What the map gets right, and what it hides

The map is honest about the physical footprint: it shows you where the labs, plants, and offices are, and where cost discipline is closing or shrinking them. That is genuinely useful for anyone deciding where to build a career or whether a region is concentrated around one employer.

But the map has a systematic blind spot, and it is the one that matters most to this audience. The remote clinical workforce, the CRAs, data managers, biostatisticians, and medical writers who work from home across many states, does not plot anywhere, because those cuts rarely trip a WARN filing. The map shows the buildings emptying. It cannot show the distributed workforce thinning. The most important layoffs for clinical research are the ones with no address at all.

That is the part only the people in it can report. If your team was cut and it never showed up on any map, that is not a gap in the story. It is the story. Post it, and add your datapoint, so the community can see what the public map leaves blank.